Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 4/20 | 0.47 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | NOS2 | P35228 | 4/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2739650 | 0.80 | CCR1 (0.57) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL31672761 | 0.77 | CCR1 (0.53) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL31691996 | 0.77 | CCR1 (0.53) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL23743940 | 0.76 | CCR1 (0.48) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL1662456 | 0.74 | CCR1 (0.55) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL11327112 | 0.74 | CCR1 (0.55) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL15212096 | 0.74 | NOS3 (0.57) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL21784460 | 0.74 | CCR1 (0.50) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL21718449 | 0.71 | CCR1 (0.47) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL22601564 | 0.70 | CA1 (0.41) | PLAUCYP1A2CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745286-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170042871-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042871-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | CCR1 2168/4885CCR5 1098/4885CCR8 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.